Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
34
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Valente Nancy | Director | 4 | $0 | $0 | 2023-03-10 |
| Mehra Uneek | Principal Financial Officer | 9 | $0 | $234.3K | 2023-03-10 |
| Merendino Lauren | Chief Commercial Officer | 11 | $0 | $192.5K | 2023-03-10 |
| Sumitomo Chemical Co., Ltd. | 10% Owner | 29 | $1.41B | $0 | 2023-03-10 |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | 105 | $0 | $3.91M | 2023-03-10 |
| Lang Matthew | General Counsel & Corp. Secy. | 63 | $0 | $3.98M | 2023-03-10 |
| Curran Terrie | Director | 25 | $0 | $1.34M | 2023-03-10 |
| Gulfo Adele M. | Director | 8 | $0 | $0 | 2023-03-10 |
| Marek David C | Principal Executive Officer | 17 | $0 | $1.19M | 2023-03-10 |
| GUINAN MARK | Director | 10 | $0 | $0 | 2023-03-10 |
| POTTER MYRTLE S | Director | 10 | $0 | $0 | 2023-03-10 |
| Sumitomo Pharma Co., Ltd. | 10% Owner | 36 | $26.05M | $0 | 2023-03-03 |
| Sumitovant Biopharma Ltd. | 10% Owner | 27 | $19.24M | $0 | 2021-09-28 |
| KARBE FRANK | Principal Fin'l & Accounting | 55 | $72.8K | $1.59M | 2021-07-07 |
| Sebelius Kathleen | Director | 9 | $44.8K | $0 | 2020-09-15 |
| Sablich Kim | Chief Commercial Officer | 14 | $0 | $115.7K | 2020-04-03 |
| Seely Lynn | Principal Executive Officer | 6 | $0 | $0 | 2020-04-03 |
| Roivant Sciences Ltd. | 10% Owner | 14 | $106.37M | $0 | 2019-12-27 |
| Torti Frank | Director | 2 | $0 | $0 | 2019-08-23 |
| Dexcel Pharma Technologies Ltd. | 10% Owner | 1 | $20.00M | $0 | 2019-06-04 |
| SoftBank Vision Fund L.P. | 10% Owner | 1 | $20.00M | $0 | 2019-06-04 |
| Lo Andrew | 10% Owner | 2 | $42.50M | $0 | 2019-06-04 |
| Viking Global Opportunities Illiquid Investments Sub-Master LP | 10% Owner | 1 | $20.00M | $0 | 2019-06-04 |
| Viking Long Fund Master Ltd. | 10% Owner | 1 | $20.00M | $0 | 2019-06-04 |
| QVT Fund V LP | Director, 10% Owner | 2 | $42.50M | $0 | 2019-06-04 |
| Machado Patrick | 10% Owner | 2 | $42.50M | $0 | 2019-06-04 |
| Altmeyer Mark | Director | 4 | $46.8K | $0 | 2018-08-31 |
| SVF GP (Jersey) Ltd | 10% Owner | 1 | $22.50M | $0 | 2018-04-02 |
| Dexxon Holdings Ltd. | 10% Owner | 1 | $22.50M | $0 | 2018-04-02 |
| VGE III Portfolio Ltd. | 10% Owner | 1 | $22.50M | $0 | 2018-04-02 |
| VIKING GLOBAL INVESTORS LP | 10% Owner | 1 | $22.50M | $0 | 2018-04-02 |
| Takeda A/S | 10% Owner | 2 | $138.54M | $138.54M | 2018-03-19 |
| DeVeydt Wayne S | Director | 2 | $0 | $0 | 2017-08-18 |
| Takeda Pharmaceuticals International AG | 10% Owner | 12 | $0 | $0 | 2017-04-17 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 134,464 | — | $0 | 0 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 79,472 | — | $0 | 0 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 103,703 | — | $0 | 0 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 63,717 | — | $0 | 0 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 155,300 | — | $0 | 0 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 65,863 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 33,846 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,096 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,603 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 5,250 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 22,500 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 22,500 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 11,154 | — | $0 | 0 | SEC↗ |
| GUINAN MARK | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 58,608 | — | $0 | 0 | SEC↗ |
| GUINAN MARK | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 45,000 | — | $0 | 0 | SEC↗ |
| GUINAN MARK | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,603 | — | $0 | 0 | SEC↗ |
| GUINAN MARK | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,096 | — | $0 | 0 | SEC↗ |
| Gulfo Adele M. | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,603 | — | $0 | 0 | SEC↗ |
| Gulfo Adele M. | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,096 | — | $0 | 0 | SEC↗ |
| Gulfo Adele M. | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 45,000 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 220,000 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 87,050 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 111,111 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 90,310 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 152,110 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer deriv | 2023-03-10 | 2023-03-10 | 170,396 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 204,808 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 306,427 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 208,218 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 134,567 | — | $0 | 0 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 111,111 | — | $0 | 0 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 165,192 | — | $0 | 0 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 103,703 | — | $0 | 0 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | D To issuer deriv | 2023-03-10 | 2023-03-10 | 123,300 | — | $0 | 0 | SEC↗ |
| POTTER MYRTLE S | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 45,000 | — | $0 | 0 | SEC↗ |
| POTTER MYRTLE S | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 58,608 | — | $0 | 0 | SEC↗ |
| POTTER MYRTLE S | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,603 | — | $0 | 0 | SEC↗ |
| POTTER MYRTLE S | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 21,096 | — | $0 | 0 | SEC↗ |
| Valente Nancy | Director | D To issuer deriv | 2023-03-10 | 2023-03-10 | 36,892 | — | $0 | 0 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2023-03-10 | 2023-03-10 | 51,599,200 | $27.00 | $1.39B | 45,798,176 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer | 2023-03-10 | 2023-03-10 | 86,602 | — | $0 | 160,082 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | D To issuer | 2023-03-10 | 2023-03-10 | 160,082 | — | $0 | 0 | SEC↗ |
| Curran Terrie | Director | D To issuer | 2023-03-10 | 2023-03-10 | 3,673 | — | $0 | 0 | SEC↗ |
| GUINAN MARK | Director | D To issuer | 2023-03-10 | 2023-03-10 | 3,673 | — | $0 | 0 | SEC↗ |
| Gulfo Adele M. | Director | D To issuer | 2023-03-10 | 2023-03-10 | 3,673 | — | $0 | 0 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer | 2023-03-10 | 2023-03-10 | 113,145 | — | $0 | 241,158 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | D To issuer | 2023-03-10 | 2023-03-10 | 241,158 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer | 2023-03-10 | 2023-03-10 | 321,924 | — | $0 | 0 | SEC↗ |
| Marek David C | Principal Executive Officer | D To issuer | 2023-03-10 | 2023-03-10 | 95,675 | — | $0 | 321,924 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | D To issuer | 2023-03-10 | 2023-03-10 | 181,972 | — | $0 | 0 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | D To issuer | 2023-03-10 | 2023-03-10 | 20,724 | — | $0 | 181,972 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | D To issuer | 2023-03-10 | 2023-03-10 | 147,747 | — | $0 | 0 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | D To issuer | 2023-03-10 | 2023-03-10 | 21,791 | — | $0 | 147,747 | SEC↗ |
| POTTER MYRTLE S | Director | D To issuer | 2023-03-10 | 2023-03-10 | 3,673 | — | $0 | 0 | SEC↗ |
| Valente Nancy | Director | D To issuer | 2023-03-10 | 2023-03-10 | 3,673 | — | $0 | 0 | SEC↗ |
| Sumitomo Pharma Co., Ltd. | 10% Owner | J Other deriv | 2023-03-03 | 2023-03-06 | 1 | — | $0 | 1 | SEC↗ |
| Sumitomo Pharma Co., Ltd. | 10% Owner | J Other | 2023-03-03 | 2023-03-06 | 4,243,005 | — | $0 | 45,798,176 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2023-01-18 | 2023-01-20 | 1,109 | $26.89 | $29.8K | 246,684 | SEC↗ |
| Marek David C | Principal Executive Officer | S Sale | 2023-01-18 | 2023-01-20 | 8,037 | $26.89 | $216.1K | 417,599 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | S Sale | 2023-01-18 | 2023-01-20 | 2,008 | $26.89 | $54.0K | 169,538 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2023-01-18 | 2023-01-20 | 1,272 | $26.89 | $34.2K | 354,303 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2023-01-04 | 2023-01-05 | 2,779 | $26.90 | $74.8K | 355,575 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2023-01-04 | 2023-01-05 | 2,251 | $26.90 | $60.6K | 247,793 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | S Sale | 2022-12-16 | 2022-12-20 | 2,241 | $26.75 | $59.9K | 202,696 | SEC↗ |
| Valente Nancy | Director | A Award | 2022-10-26 | 2022-10-28 | 9,859 | — | $0 | 9,859 | SEC↗ |
| POTTER MYRTLE S | Director | A Award | 2022-10-26 | 2022-10-28 | 9,859 | — | $0 | 9,859 | SEC↗ |
| Gulfo Adele M. | Director | A Award | 2022-10-26 | 2022-10-28 | 9,859 | — | $0 | 9,859 | SEC↗ |
| GUINAN MARK | Director | A Award | 2022-10-26 | 2022-10-28 | 9,859 | — | $0 | 9,859 | SEC↗ |
| Curran Terrie | Director | A Award | 2022-10-26 | 2022-10-28 | 9,859 | — | $0 | 9,859 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-10-18 | 2022-10-20 | 1,604 | $25.20 | $40.4K | 250,044 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-10-18 | 2022-10-20 | 1,933 | $25.20 | $48.7K | 358,354 | SEC↗ |
| Marek David C | Principal Executive Officer | S Sale | 2022-10-18 | 2022-10-20 | 11,156 | $25.20 | $281.1K | 425,636 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | S Sale | 2022-10-18 | 2022-10-20 | 1,703 | $25.20 | $42.9K | 171,546 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-10-04 | 2022-10-06 | 3,679 | $24.40 | $89.8K | 360,287 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-10-04 | 2022-10-06 | 2,738 | $24.40 | $66.8K | 251,648 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | S Sale | 2022-09-16 | 2022-09-20 | 9,243 | $18.86 | $174.3K | 204,937 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-08-15 | 2022-08-16 | 31,214 | $18.23 | $569.0K | 363,966 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | A Award | 2022-08-12 | 2022-08-16 | 124,780 | — | $0 | 395,180 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-07-18 | 2022-07-20 | 1,606 | $12.87 | $20.7K | 254,386 | SEC↗ |
| Marek David C | Principal Executive Officer | S Sale | 2022-07-18 | 2022-07-20 | 11,164 | $12.87 | $143.7K | 436,792 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | S Sale | 2022-07-18 | 2022-07-20 | 1,704 | $12.87 | $21.9K | 173,249 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-07-18 | 2022-07-20 | 1,935 | $12.87 | $24.9K | 270,400 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-07-06 | 2022-07-08 | 3,702 | $13.40 | $49.6K | 272,335 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-07-06 | 2022-07-08 | 2,755 | $13.40 | $36.9K | 255,992 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-05-27 | 2022-06-01 | 1,382 | $10.07 | $13.9K | 258,747 | SEC↗ |
| Marek David C | Principal Executive Officer | S Sale | 2022-04-19 | 2022-04-21 | 24,594 | $10.45 | $257.0K | 447,956 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | S Sale | 2022-04-19 | 2022-04-21 | 7,049 | $10.45 | $73.7K | 174,953 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-04-19 | 2022-04-21 | 4,632 | $10.45 | $48.4K | 260,129 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-04-19 | 2022-04-21 | 8,002 | $10.45 | $83.6K | 276,037 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award deriv | 2022-04-15 | 2022-04-19 | 204,808 | — | $0 | 204,808 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award | 2022-04-15 | 2022-04-19 | 134,567 | — | $0 | 472,550 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | A Award | 2022-04-15 | 2022-04-19 | 103,703 | — | $0 | 182,002 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | A Award | 2022-04-15 | 2022-04-19 | 111,111 | — | $0 | 284,039 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | A Award | 2022-04-15 | 2022-04-19 | 103,703 | — | $0 | 264,761 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | A Award | 2022-04-15 | 2022-04-19 | 111,111 | — | $0 | 214,180 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-04-05 | 2022-04-07 | 1,922 | $13.78 | $26.5K | 161,058 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-04-05 | 2022-04-07 | 2,436 | $13.78 | $33.6K | 172,928 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-03-01 | 2022-03-03 | 1,362 | $13.35 | $18.2K | 162,980 | SEC↗ |
| Marek David C | Principal Executive Officer | S Sale | 2022-01-19 | 2022-01-21 | 19,882 | $14.68 | $291.9K | 337,983 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2022-01-04 | 2022-01-06 | 2,271 | $16.27 | $36.9K | 164,342 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2022-01-04 | 2022-01-06 | 4,475 | $16.27 | $72.8K | 175,364 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-11-29 | 2021-12-01 | 1,978 | $19.30 | $38.2K | 166,613 | SEC↗ |
| Valente Nancy | Director | A Award deriv | 2021-11-05 | 2021-11-09 | 36,892 | — | $0 | 36,892 | SEC↗ |
| POTTER MYRTLE S | Director | A Award deriv | 2021-11-05 | 2021-11-09 | 21,096 | — | $0 | 21,096 | SEC↗ |
| Gulfo Adele M. | Director | A Award deriv | 2021-11-05 | 2021-11-09 | 21,096 | — | $0 | 21,096 | SEC↗ |
| GUINAN MARK | Director | A Award deriv | 2021-11-05 | 2021-11-09 | 21,096 | — | $0 | 21,096 | SEC↗ |
| Curran Terrie | Director | A Award deriv | 2021-11-05 | 2021-11-09 | 21,096 | — | $0 | 21,096 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-11-04 | 2021-11-05 | 3,100 | — | $0 | 155,300 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-11-04 | 2021-11-05 | 3,100 | $7.78 | $24.1K | 171,691 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-11-04 | 2021-11-05 | 3,100 | $24.02 | $74.5K | 168,591 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-11-03 | 2021-11-05 | 700 | — | $0 | 158,400 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-11-03 | 2021-11-05 | 700 | $24.00 | $16.8K | 168,591 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-11-03 | 2021-11-05 | 700 | $7.78 | $5.4K | 169,291 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2021-10-05 | 2021-10-07 | 6,671 | $21.62 | $144.2K | 179,839 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-10-05 | 2021-10-07 | 2,738 | $21.62 | $59.2K | 168,591 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-28 | 2021-09-30 | 20,677 | $22.85 | $472.5K | 50,041,181 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-09-27 | 2021-09-29 | 7,000 | — | $0 | 159,100 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-27 | 2021-09-28 | 2,232 | $24.86 | $55.5K | 50,020,504 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-27 | 2021-09-28 | 45,768 | $24.19 | $1.11M | 50,018,272 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-09-27 | 2021-09-29 | 7,000 | $7.78 | $54.5K | 178,329 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-09-27 | 2021-09-29 | 7,000 | $24.32 | $170.2K | 171,329 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-24 | 2021-09-28 | 36,000 | $23.40 | $842.4K | 49,972,504 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-23 | 2021-09-24 | 5,311 | $23.49 | $124.8K | 49,936,504 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-23 | 2021-09-24 | 49,467 | $23.01 | $1.14M | 49,931,193 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-22 | 2021-09-24 | 84,018 | $21.96 | $1.85M | 49,881,726 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-21 | 2021-09-22 | 43,000 | $22.48 | $966.6K | 49,797,708 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-20 | 2021-09-22 | 38,273 | $22.10 | $845.8K | 49,754,708 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-17 | 2021-09-20 | 37,913 | $22.79 | $864.0K | 49,716,435 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-16 | 2021-09-20 | 50,000 | $21.75 | $1.09M | 49,678,522 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | A Award deriv | 2021-09-15 | 2021-09-17 | 165,192 | — | $0 | 165,192 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-15 | 2021-09-16 | 89,864 | $21.98 | $1.98M | 49,628,522 | SEC↗ |
| Mehra Uneek | Principal Financial Officer | A Award | 2021-09-15 | 2021-09-17 | 103,069 | — | $0 | 103,069 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-14 | 2021-09-16 | 6,172 | $22.76 | $140.5K | 49,538,658 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-14 | 2021-09-16 | 65,128 | $22.04 | $1.44M | 49,532,486 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-13 | 2021-09-14 | 30,028 | $23.91 | $718.0K | 49,467,358 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-13 | 2021-09-14 | 53,150 | $23.09 | $1.23M | 49,437,330 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-10 | 2021-09-14 | 30,000 | $25.11 | $753.3K | 49,384,180 | SEC↗ |
| Curran Terrie | Director | M Exercise deriv | 2021-09-09 | 2021-09-13 | 4,850 | — | $0 | 5,250 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-09 | 2021-09-10 | 37,000 | $25.52 | $944.2K | 49,354,180 | SEC↗ |
| Curran Terrie | Director | M Exercise | 2021-09-09 | 2021-09-13 | 4,850 | $7.65 | $37.1K | 4,850 | SEC↗ |
| Curran Terrie | Director | S Sale | 2021-09-09 | 2021-09-13 | 4,850 | $25.58 | $124.1K | 0 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-09-08 | 2021-09-10 | 21,902 | $25.74 | $563.8K | 49,317,180 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-07 | 2021-09-08 | 4,913 | $27.12 | $133.2K | 49,295,278 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-07 | 2021-09-08 | 28,287 | $26.08 | $737.7K | 49,290,365 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-03 | 2021-09-08 | 29,822 | $26.74 | $797.4K | 49,260,700 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-09-03 | 2021-09-08 | 1,378 | $27.29 | $37.6K | 49,262,078 | SEC↗ |
| Curran Terrie | Director | M Exercise deriv | 2021-09-02 | 2021-09-03 | 37,135 | — | $0 | 10,100 | SEC↗ |
| Curran Terrie | Director | S Sale | 2021-09-02 | 2021-09-03 | 37,135 | $25.03 | $929.5K | 0 | SEC↗ |
| Curran Terrie | Director | M Exercise | 2021-09-02 | 2021-09-03 | 37,135 | $7.65 | $284.1K | 37,135 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-02 | 2021-09-03 | 22,209 | $25.25 | $560.8K | 49,189,985 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-02 | 2021-09-03 | 35,045 | $26.46 | $927.3K | 49,225,030 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-02 | 2021-09-03 | 5,848 | $26.95 | $157.6K | 49,230,878 | SEC↗ |
| Curran Terrie | Director | M Exercise deriv | 2021-09-01 | 2021-09-03 | 11,373 | — | $0 | 47,235 | SEC↗ |
| Curran Terrie | Director | S Sale | 2021-09-01 | 2021-09-03 | 11,373 | $25.00 | $284.3K | 0 | SEC↗ |
| Curran Terrie | Director | M Exercise | 2021-09-01 | 2021-09-03 | 11,373 | $7.65 | $87.0K | 11,373 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-09-01 | 2021-09-03 | 40,000 | $24.83 | $993.2K | 49,167,776 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-31 | 2021-09-01 | 39,000 | $24.28 | $946.9K | 49,127,776 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-08-30 | 2021-08-31 | 21,000 | — | $0 | 166,100 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-08-30 | 2021-08-31 | 21,000 | $7.78 | $163.4K | 192,329 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-08-30 | 2021-08-31 | 21,000 | $24.05 | $505.1K | 171,329 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-30 | 2021-09-01 | 70,000 | $23.92 | $1.67M | 49,088,776 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-08-27 | 2021-08-30 | 37,038 | $23.17 | $858.2K | 49,018,776 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-08-27 | 2021-08-31 | 1,978 | $22.69 | $44.9K | 171,329 | SEC↗ |
| Sumitomo Chemical Co., Ltd. | 10% Owner | P Buy | 2021-08-26 | 2021-08-30 | 40,000 | $22.67 | $906.8K | 48,981,738 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-08-25 | 2021-08-26 | 28,709 | $22.44 | $644.2K | 48,941,738 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-08-24 | 2021-08-26 | 34,299 | $22.37 | $767.3K | 48,913,029 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-08-23 | 2021-08-24 | 30,390 | $22.45 | $682.3K | 48,878,730 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-08-23 | 2021-08-24 | 25,057 | $22.13 | $554.5K | 48,848,340 | SEC↗ |
| Sumitovant Biopharma Ltd. | 10% Owner | P Buy | 2021-08-20 | 2021-08-24 | 46,478 | $20.86 | $969.5K | 48,823,283 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-19 | 2021-08-20 | 46,792 | $21.51 | $1.01M | 48,776,805 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-18 | 2021-08-20 | 17,116 | $21.45 | $367.1K | 48,730,013 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-17 | 2021-08-18 | 23,549 | $20.89 | $491.9K | 48,712,897 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-16 | 2021-08-18 | 5,382 | $21.94 | $118.1K | 48,689,348 | SEC↗ |
| Dainippon Sumitomo Pharma Co L | 10% Owner | P Buy | 2021-08-16 | 2021-08-18 | 42,785 | $21.29 | $910.9K | 48,683,966 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2021-07-09 | 2021-07-13 | 6,954 | $21.52 | $149.7K | 186,510 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2021-07-07 | 2021-07-09 | 3,232 | $21.75 | $70.3K | 212,296 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-07-07 | 2021-07-09 | 2,777 | $21.75 | $60.4K | 173,307 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-05-28 | 2021-06-02 | 1,300 | — | $0 | 187,100 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-05-28 | 2021-06-02 | 1,300 | $24.00 | $31.2K | 177,867 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-05-28 | 2021-06-02 | 1,300 | $7.78 | $10.1K | 179,167 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-05-28 | 2021-06-02 | 1,783 | $24.00 | $42.8K | 176,084 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-05-26 | 2021-05-28 | 2,867 | — | $0 | 188,400 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-05-26 | 2021-05-28 | 9,833 | — | $0 | 63,717 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-05-26 | 2021-05-28 | 12,700 | $24.23 | $307.7K | 177,867 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-05-26 | 2021-05-28 | 12,700 | $7.78 | $98.8K | 190,567 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | A Award deriv | 2021-04-15 | 2021-04-19 | 123,300 | — | $0 | 123,300 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award deriv | 2021-04-15 | 2021-04-19 | 208,218 | — | $0 | 208,218 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | A Award deriv | 2021-04-15 | 2021-04-19 | 97,534 | — | $0 | 97,534 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | A Award deriv | 2021-04-15 | 2021-04-19 | 79,472 | — | $0 | 79,472 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | A Award deriv | 2021-04-15 | 2021-04-19 | 90,310 | — | $0 | 90,310 | SEC↗ |
| Merendino Lauren | Chief Commercial Officer | A Award | 2021-04-15 | 2021-04-19 | 78,299 | — | $0 | 78,299 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award | 2021-04-15 | 2021-04-19 | 134,789 | — | $0 | 357,865 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | A Award | 2021-04-15 | 2021-04-19 | 63,138 | — | $0 | 215,528 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | A Award | 2021-04-15 | 2021-04-19 | 51,446 | — | $0 | 177,867 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | A Award | 2021-04-15 | 2021-04-19 | 58,461 | — | $0 | 193,464 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2021-04-06 | 2021-04-08 | 11,080 | $18.63 | $206.4K | 152,390 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2021-04-06 | 2021-04-08 | 10,862 | $18.62 | $202.3K | 135,003 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-04-06 | 2021-04-08 | 8,114 | $18.63 | $151.2K | 126,421 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2021-03-19 | 2021-03-23 | 7,000 | — | $0 | 73,550 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2021-03-19 | 2021-03-23 | 7,000 | $7.78 | $54.5K | 141,535 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-03-19 | 2021-03-23 | 7,000 | $24.17 | $169.2K | 134,535 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2021-03-15 | 2021-03-17 | 30,000 | — | $0 | 220,000 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2021-03-15 | 2021-03-17 | 30,000 | $7.78 | $233.4K | 175,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2021-03-15 | 2021-03-17 | 30,000 | $25.07 | $752.1K | 145,865 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2021-03-01 | 2021-03-03 | 1,513 | $22.55 | $34.1K | 134,535 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2021-02-16 | 2021-02-18 | 750 | — | $0 | 181,744 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2021-02-16 | 2021-02-18 | 750 | $21.40 | $16.0K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2021-02-16 | 2021-02-18 | 750 | $5.11 | $3.8K | 164,220 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2021-01-28 | 2021-02-01 | 300 | — | $0 | 182,494 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2021-01-28 | 2021-02-01 | 300 | $5.11 | $1.5K | 163,770 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2021-01-28 | 2021-02-01 | 300 | $24.00 | $7.2K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2021-01-15 | 2021-01-20 | 750 | — | $0 | 182,794 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award deriv | 2021-01-15 | 2021-01-20 | 306,427 | — | $0 | 306,427 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2021-01-15 | 2021-01-20 | 750 | $21.50 | $16.1K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2021-01-15 | 2021-01-20 | 750 | $5.11 | $3.8K | 164,220 | SEC↗ |
| Marek David C | Principal Executive Officer | A Award | 2021-01-15 | 2021-01-20 | 223,076 | — | $0 | 223,076 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-12-28 | 2020-12-30 | 11,800 | — | $0 | 183,544 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-12-28 | 2020-12-30 | 11,800 | $5.11 | $60.3K | 175,270 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-12-28 | 2020-12-30 | 11,800 | $30.00 | $354.0K | 163,470 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-12-18 | 2020-12-22 | 10,000 | — | $0 | 250,000 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-12-18 | 2020-12-22 | 2,000 | — | $0 | 191,267 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-12-18 | 2020-12-22 | 300 | $26.24 | $7.9K | 145,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-12-18 | 2020-12-22 | 10,000 | $7.78 | $77.8K | 155,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-12-18 | 2020-12-22 | 9,700 | $25.38 | $246.2K | 146,165 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-12-18 | 2020-12-22 | 2,000 | $7.78 | $15.6K | 138,048 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-12-18 | 2020-12-22 | 2,000 | $26.00 | $52.0K | 136,048 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-12-15 | 2020-12-17 | 1,050 | — | $0 | 195,344 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-12-15 | 2020-12-17 | 7,000 | — | $0 | 193,267 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-12-15 | 2020-12-17 | 670 | $24.45 | $16.4K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-12-15 | 2020-12-17 | 1,050 | $5.11 | $5.4K | 164,520 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-12-15 | 2020-12-17 | 380 | $23.63 | $9.0K | 164,140 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-12-15 | 2020-12-17 | 3,467 | $24.18 | $83.8K | 136,048 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-12-15 | 2020-12-17 | 3,533 | $23.66 | $83.6K | 139,515 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-12-15 | 2020-12-17 | 7,000 | $7.78 | $54.5K | 143,048 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-12-10 | 2020-12-11 | 19,400 | — | $0 | 260,000 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-12-10 | 2020-12-14 | 10,000 | — | $0 | 200,267 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-12-10 | 2020-12-11 | 19,400 | $7.78 | $150.9K | 165,265 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-12-10 | 2020-12-11 | 19,400 | $25.20 | $488.9K | 145,865 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-12-10 | 2020-12-14 | 10,000 | $26.04 | $260.4K | 136,048 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-12-10 | 2020-12-14 | 10,000 | $7.78 | $77.8K | 146,048 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-12-09 | 2020-12-11 | 600 | — | $0 | 279,400 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-12-09 | 2020-12-11 | 600 | $7.78 | $4.7K | 146,465 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-12-09 | 2020-12-11 | 600 | $25.08 | $15.0K | 145,865 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-11-30 | 2020-12-02 | 1,500 | — | $0 | 196,394 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-11-30 | 2020-12-02 | 1,500 | $24.00 | $36.0K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-11-30 | 2020-12-02 | 1,500 | $5.11 | $7.7K | 164,970 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-11-30 | 2020-12-02 | 1,978 | $23.65 | $46.8K | 136,048 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-11-17 | 2020-11-19 | 7,000 | — | $0 | 210,267 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-11-17 | 2020-11-19 | 750 | — | $0 | 197,894 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-11-17 | 2020-11-19 | 7,000 | $20.00 | $140.0K | 138,026 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-11-17 | 2020-11-19 | 7,000 | $7.78 | $54.5K | 145,026 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-11-17 | 2020-11-19 | 750 | $5.11 | $3.8K | 164,220 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-11-17 | 2020-11-19 | 750 | $20.00 | $15.0K | 163,470 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-11-13 | 2020-11-17 | 7,000 | — | $0 | 217,267 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-11-13 | 2020-11-17 | 750 | — | $0 | 198,644 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-11-13 | 2020-11-17 | 7,000 | $20.00 | $140.0K | 138,026 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-11-13 | 2020-11-17 | 7,000 | $7.78 | $54.5K | 145,026 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-11-13 | 2020-11-17 | 750 | $5.11 | $3.8K | 164,220 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-11-13 | 2020-11-17 | 750 | $20.00 | $15.0K | 163,470 | SEC↗ |
| Sebelius Kathleen | Director | A Award deriv | 2020-09-15 | 2020-09-17 | 21,603 | — | $0 | 21,603 | SEC↗ |
| POTTER MYRTLE S | Director | A Award deriv | 2020-09-15 | 2020-09-17 | 21,603 | — | $0 | 21,603 | SEC↗ |
| Gulfo Adele M. | Director | A Award deriv | 2020-09-15 | 2020-09-17 | 21,603 | — | $0 | 21,603 | SEC↗ |
| GUINAN MARK | Director | A Award deriv | 2020-09-15 | 2020-09-17 | 21,603 | — | $0 | 21,603 | SEC↗ |
| Curran Terrie | Director | A Award deriv | 2020-09-15 | 2020-09-17 | 21,603 | — | $0 | 21,603 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-09-15 | 2020-09-17 | 7,000 | — | $0 | 224,267 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-09-15 | 2020-09-17 | 750 | — | $0 | 199,394 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-09-15 | 2020-09-17 | 100 | $22.45 | $2.2K | 138,026 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-09-15 | 2020-09-17 | 7,000 | $7.78 | $54.5K | 145,026 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-09-15 | 2020-09-17 | 6,900 | $21.76 | $150.1K | 138,126 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-09-15 | 2020-09-17 | 750 | $5.11 | $3.8K | 164,220 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-09-15 | 2020-09-17 | 750 | $21.73 | $16.3K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-08-31 | 2020-09-01 | 21,150 | — | $0 | 200,144 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-08-31 | 2020-09-02 | 11,307 | — | $0 | 231,267 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-08-31 | 2020-09-02 | 26,700 | — | $0 | 280,000 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-08-31 | 2020-09-01 | 21,150 | $20.01 | $423.2K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-08-31 | 2020-09-01 | 21,150 | $5.11 | $108.1K | 184,620 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-08-31 | 2020-09-02 | 11,307 | $20.01 | $226.3K | 138,026 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-08-31 | 2020-09-02 | 11,307 | $7.78 | $88.0K | 149,333 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-08-31 | 2020-09-02 | 26,700 | $7.78 | $207.7K | 172,565 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-08-31 | 2020-09-02 | 26,700 | $20.05 | $535.3K | 145,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-08-28 | 2020-08-28 | 2,600 | — | $0 | 306,700 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-08-28 | 2020-08-31 | 267 | — | $0 | 65,863 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-08-28 | 2020-08-31 | 1,791 | — | $0 | 242,574 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-08-28 | 2020-09-01 | 3,650 | — | $0 | 221,294 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-08-28 | 2020-08-28 | 2,600 | $20.02 | $52.1K | 145,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-08-28 | 2020-08-28 | 2,600 | $7.78 | $20.2K | 148,465 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-08-28 | 2020-08-31 | 2,058 | $7.78 | $16.0K | 140,084 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-08-28 | 2020-08-31 | 2,058 | $20.01 | $41.2K | 138,026 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | S Sale | 2020-08-28 | 2020-09-01 | 3,650 | $20.04 | $73.1K | 163,470 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise | 2020-08-28 | 2020-09-01 | 3,650 | $5.11 | $18.7K | 167,120 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-08-27 | 2020-08-31 | 7,089 | $18.80 | $133.3K | 138,026 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-08-26 | 2020-08-28 | 100 | — | $0 | 309,300 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-08-26 | 2020-08-28 | 100 | $20.00 | $2.0K | 145,865 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise | 2020-08-26 | 2020-08-28 | 100 | $7.78 | $778 | 145,965 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise deriv | 2020-08-19 | 2020-08-21 | 635 | — | $0 | 244,365 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | M Exercise deriv | 2020-08-19 | 2020-08-21 | 600 | — | $0 | 309,400 | SEC↗ |
| KARBE FRANK | Principal Fin'l & Accounting | M Exercise deriv | 2020-08-19 | 2020-08-21 | 700 | — | $0 | 224,944 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | M Exercise | 2020-08-19 | 2020-08-21 | 635 | $7.78 | $4.9K | 145,750 | SEC↗ |
| Arjona Ferreira Juan Camilo | Chief Medical Officer | S Sale | 2020-08-19 | 2020-08-21 | 635 | $20.00 | $12.7K | 145,115 | SEC↗ |
| Lang Matthew | General Counsel & Corp. Secy | S Sale | 2020-08-19 | 2020-08-21 | 600 | $20.00 | $12.0K | 145,865 | SEC↗ |